Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients
Elif Irem Sarihan MD
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorEduardo Pérez-Palma PhD
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorLisa-Marie Niestroj PhD
Cologne Center for Genomics, University of Cologne, Cologne, Germany
Search for more papers by this authorDouglas Loesch BA, AS
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA
Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorMiguel Inca-Martinez BS
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorAndrea R.V.R. Horimoto PhD
Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA
Search for more papers by this authorMario Cornejo-Olivas MD
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
Center for Global Health, Universidad Peruana Cayetano Heredia, Lima, Peru
Search for more papers by this authorLuis Torres MD
Movement Disorders Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru
Search for more papers by this authorPilar Mazzetti MD
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru
Search for more papers by this authorCarlos Cosentino MD
Movement Disorders Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru
Search for more papers by this authorElison Sarapura-Castro MD
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
Search for more papers by this authorAndrea Rivera-Valdivia MD
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
Search for more papers by this authorElena Dieguez MD
Neurology Institute, Universidad de la República, Montevideo, Uruguay
Search for more papers by this authorVictor Raggio MD
Department of Genetics, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
Search for more papers by this authorAndres Lescano MD
Neurology Institute, Universidad de la República, Montevideo, Uruguay
Search for more papers by this authorVitor Tumas MD, PhD
Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil
Search for more papers by this authorVanderci Borges MD, PhD
Movement Disorders Unit, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorHenrique B. Ferraz MD, PhD
Movement Disorders Unit, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorCarlos R. Rieder PhD
Departamento de Neurologia, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil
Search for more papers by this authorArtur F. Schumacher-Schuh MD, PhD
Serviço de Neurologia, Hospital de Clínicas de Porto Alegre and Departamento de Farmacologia, Universidade Federal do Rio Grande do Su, Porto Alegre, Brazil
Search for more papers by this authorBruno L. Santos-Lobato MD, PhD
Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Brazil
Search for more papers by this authorCarlos Velez-Pardo PhD
Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Colombia
Search for more papers by this authorMarlene Jimenez-Del-Rio PhD
Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Colombia
Search for more papers by this authorFrancisco Lopera MD
Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Colombia
Search for more papers by this authorSonia Moreno PhD
Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Colombia
Search for more papers by this authorPedro Chana-Cuevas MD
CETRAM, Facultad de Ciencias Medicas, Universidad de Santiago de Chile, Santiago de Chile, Chile
Search for more papers by this authorWilliam Fernandez MD
Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia
Search for more papers by this authorGonzalo Arboleda MD, PhD
Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia
Search for more papers by this authorHumberto Arboleda MD, MS
Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia
Search for more papers by this authorCarlos E. Arboleda-Bustos PhD
Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia
Search for more papers by this authorDora Yearout BS
Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA
Department of Neurology, University of Washington, Seattle, Washington, USA
Search for more papers by this authorCyrus P. Zabetian MD, MS
Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA
Department of Neurology, University of Washington, Seattle, Washington, USA
Search for more papers by this authorTimothy A. Thornton PhD
Department of Biostatistics, University of Washington, Seattle, Washington, USA
Search for more papers by this authorTimothy D. O'Connor PhD
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA
Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorDennis Lal PhD
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Cologne Center for Genomics, University of Cologne, Cologne, Germany
Stanley Center for Psychiatric Research, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA
Epilepsy Center & Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorCorresponding Author
Ignacio F. Mata PhD
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA
Department of Neurology, University of Washington, Seattle, Washington, USA
All the data for this article were generated while I.F.M. was affiliated with the VA Puget Sound and the University of Washington.
Correspondence to: Dr. Ignacio F. Mata, Lerner Research Institute R4-006, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA; E-mail: [email protected]Search for more papers by this authorLatin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD)‡
Search for more papers by this authorElif Irem Sarihan MD
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorEduardo Pérez-Palma PhD
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorLisa-Marie Niestroj PhD
Cologne Center for Genomics, University of Cologne, Cologne, Germany
Search for more papers by this authorDouglas Loesch BA, AS
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA
Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorMiguel Inca-Martinez BS
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorAndrea R.V.R. Horimoto PhD
Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, Washington, USA
Search for more papers by this authorMario Cornejo-Olivas MD
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
Center for Global Health, Universidad Peruana Cayetano Heredia, Lima, Peru
Search for more papers by this authorLuis Torres MD
Movement Disorders Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru
Search for more papers by this authorPilar Mazzetti MD
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru
Search for more papers by this authorCarlos Cosentino MD
Movement Disorders Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru
Search for more papers by this authorElison Sarapura-Castro MD
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
Search for more papers by this authorAndrea Rivera-Valdivia MD
Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru
Search for more papers by this authorElena Dieguez MD
Neurology Institute, Universidad de la República, Montevideo, Uruguay
Search for more papers by this authorVictor Raggio MD
Department of Genetics, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
Search for more papers by this authorAndres Lescano MD
Neurology Institute, Universidad de la República, Montevideo, Uruguay
Search for more papers by this authorVitor Tumas MD, PhD
Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil
Search for more papers by this authorVanderci Borges MD, PhD
Movement Disorders Unit, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorHenrique B. Ferraz MD, PhD
Movement Disorders Unit, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil
Search for more papers by this authorCarlos R. Rieder PhD
Departamento de Neurologia, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil
Search for more papers by this authorArtur F. Schumacher-Schuh MD, PhD
Serviço de Neurologia, Hospital de Clínicas de Porto Alegre and Departamento de Farmacologia, Universidade Federal do Rio Grande do Su, Porto Alegre, Brazil
Search for more papers by this authorBruno L. Santos-Lobato MD, PhD
Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Brazil
Search for more papers by this authorCarlos Velez-Pardo PhD
Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Colombia
Search for more papers by this authorMarlene Jimenez-Del-Rio PhD
Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Colombia
Search for more papers by this authorFrancisco Lopera MD
Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Colombia
Search for more papers by this authorSonia Moreno PhD
Neuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Colombia
Search for more papers by this authorPedro Chana-Cuevas MD
CETRAM, Facultad de Ciencias Medicas, Universidad de Santiago de Chile, Santiago de Chile, Chile
Search for more papers by this authorWilliam Fernandez MD
Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia
Search for more papers by this authorGonzalo Arboleda MD, PhD
Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia
Search for more papers by this authorHumberto Arboleda MD, MS
Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia
Search for more papers by this authorCarlos E. Arboleda-Bustos PhD
Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia
Search for more papers by this authorDora Yearout BS
Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA
Department of Neurology, University of Washington, Seattle, Washington, USA
Search for more papers by this authorCyrus P. Zabetian MD, MS
Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA
Department of Neurology, University of Washington, Seattle, Washington, USA
Search for more papers by this authorTimothy A. Thornton PhD
Department of Biostatistics, University of Washington, Seattle, Washington, USA
Search for more papers by this authorTimothy D. O'Connor PhD
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA
Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Search for more papers by this authorDennis Lal PhD
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Cologne Center for Genomics, University of Cologne, Cologne, Germany
Stanley Center for Psychiatric Research, Broad Institute of MIT & Harvard, Cambridge, Massachusetts, USA
Epilepsy Center & Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for more papers by this authorCorresponding Author
Ignacio F. Mata PhD
Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, Ohio, USA
Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA
Department of Neurology, University of Washington, Seattle, Washington, USA
All the data for this article were generated while I.F.M. was affiliated with the VA Puget Sound and the University of Washington.
Correspondence to: Dr. Ignacio F. Mata, Lerner Research Institute R4-006, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA; E-mail: [email protected]Search for more papers by this authorLatin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD)‡
Search for more papers by this authorMembers of the Latin American Research Consortium on the Genetics of Parkinson's Disease are listed in the Appendix.
Relevant conflicts of interest/financial disclosures: The authors report no financial disclosure/conflict of interest related to the current article.
Funding agencies: Recruitment of LARGE-PD participants was funded by an International Research Program Grant from the Parkinson's Disease Foundation (2010-2012), and this work was funded by a Stanley Fahn Junior Faculty Award from the Parkinson's Foundation. This work was also supported by a research grant from the American Parkinson's Disease Association, with resources and the use of facilities at the Veterans Affairs Puget Sound Health Care System. M.J.-D.-R. and C.V.-P. were supported by the Committee for Development and Research (Comite para el desarrollo y la investigación-CODI)-Universidad de Antioquia grant 2020-31455.
ABSTRACT
Background
Parkinson's disease is the second most common neurodegenerative disorder and affects people from all ethnic backgrounds, yet little is known about the genetics of Parkinson's disease in non-European populations. In addition, the overall identification of copy number variants at a genome-wide level has been understudied in Parkinson's patients. The objective of this study was to understand the genome-wide burden of copy number variants in Latinos and its association with Parkinson's disease.
Methods
We used genome-wide genotyping data from 747 Parkinson's disease patients and 632 controls from the Latin American Research Consortium on the Genetics of Parkinson's disease.
Results
Genome-wide copy number burden analysis showed that patients were significantly enriched for copy number variants overlapping known Parkinson's disease genes compared with controls (odds ratio, 3.97; 95%CI, 1.69–10.5; P = 0.018). PRKN showed the strongest copy number burden, with 20 copy number variant carriers. These patients presented an earlier age of disease onset compared with patients with other copy number variants (median age at onset, 31 vs 57 years, respectively; P = 7.46 × 10−7).
Conclusions
We found that although overall genome-wide copy number variant burden was not significantly different, Parkinson's disease patients were significantly enriched with copy number variants affecting known Parkinson's disease genes. We also identified that of 250 patients with early-onset disease, 5.6% carried a copy number variant on PRKN in our cohort. Our study is the first to analyze genome-wide copy number variant association in Latino Parkinson's disease patients and provides insights about this complex disease in this understudied population. © 2020 International Parkinson and Movement Disorder Society
Supporting Information
Filename | Description |
---|---|
mds28353-sup-0001-Supinfo.docxWord 2007 document , 135.6 KB | Table S1. CNV characteristics showing profiles of CNVs called following QC steps in PD patients and controls Table S2. Homozygous and compound heterozygous PD patients carrying CNV in PRKN Figure S1. (A) PCA of LARGE-PD individuals included in the study, color-coded by country of origin. (B) PCA of 1000 Genomes population for comparison, color-coded by different populations. Figure S2. Kaplan–Meier estimates of PD patients carrying a CNV on a known PD gene and patients with other or no CNVs. Probability is the probability of not having symptoms associated with PD. Age at onset is time to onset of PD symptoms. Highlight around the curves shows 95% confidence intervals. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1de Lau LML, Breteler MMB. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5(6): 525–535.
- 2 GBD 2016 Parkinson's disease collaborators. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17(11): 939–953.
- 3Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012; 72(6): 893–901.
- 4Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord 2013; 28(1): 14–23.
- 5Domingo A, Klein C. Chapter 14 — Genetics of Parkinson disease. In: DH Geschwind, HL Paulson, C Klein, editors. Handbook of Clinical Neurology. Amsterdam, Netherlands: Elsevier; 2018: 211–227.
- 6Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2012; 2(1):a008888.
- 7Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997; 276(5321): 2045–2047.
- 8Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18(2): 106–108.
- 9Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55(2): 164–173.
- 10Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 2013; 28(6): 811–813.
- 11Lesage S, Anheim M, Letournel F, et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 2013; 73(4): 459–471.
- 12Singleton AB, Farrer M, Johnson J, et al. Alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302(5646): 841.
- 13Ibáñez P, Bonnet AM, Débarges B, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364(9440): 1169–1171.
- 14Chartier-Harlin M-C, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364(9440): 1167–1169.
- 15Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392(6676): 605–608.
- 16Mata IF, Lockhart PJ, Farrer MJ. Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 2004; 13(suppl_1): R127–R133.
- 17Pankratz N, Dumitriu A, Hetrick KN, et al. Copy number variation in familial Parkinson disease. PLoS One 2011; 6(8):e20988.
- 18Kim J-S, Yoo J-Y, Lee K-S, et al. Comparative genome hybridization array analysis for sporadic Parkinson's disease. Int J Neurosci 2008; 118(9): 1331–1345.
- 19Liu X, Cheng R, Ye X, et al. Increased rate of sporadic and recurrent rare genic copy number variants in Parkinson's disease among Ashkenazi Jews. Mol Genet Genomic Med 2013; 1(3): 142–154.
- 20Darvish H, Movafagh A, Omrani MD, et al. Detection of copy number changes in genes associated with Parkinson's disease in Iranian patients. Neurosci Lett 2013; 551: 75–78.
- 21Toft M, Ross OA. Copy number variation in Parkinson's disease. Genome Med 2010; 2(9): 62.
- 22Ibáñez P, Lesage S, Janin S, et al. α-Synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 2009; 66(1): 102–108.
- 23Colby SL, Ortman JM. Projections of the size and composition of the US population: 2014 to 2060, current population reports, Washington DC: Census Bureau; 2014: 25–1143. https://www.census.gov/content/dam/Census/library/publications/2015/demo/p25-1143.pdf
- 24Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature 2016; 538(7624): 161.
- 25Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157(11): 1015–1022.
- 26Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 2010; 34(3): 143–151.
- 27Zabetian CP, Mata IF. LARGE-PD: examining the genetics of Parkinson's disease in Latin America. Mov Disord 2017; 32(9): 1330–1331.
- 28Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51(6): 745–752.
- 29Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015; 4(1): 7.
- 30Niestroj L-M, Howrigan DP, Perez-Palma E, et al. Evaluation of copy number burden in specific epilepsy types from a genome-wide study of 18,564 subjects. preprint: bioRxiv 2019; doi: 10.1101/651299.
- 31 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature 2015; 526(7571): 68–74.
- 32Wang K, Li M, Hadley D, et al. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007; 17(11): 1665–1674.
- 33Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in genome-wide association studies. Bioinformatics 2010; 26(22): 2867–2873.
- 34Huang AY, Yu D, Davis LK, et al. Rare copy number variants in NRXN1 and CNTN6 increase risk for Tourette syndrome. Neuron 2017; 94(6): 1101–1111.e7.
- 35Macé A, Tuke MA, Beckmann JS, et al. New quality measure for SNP array based CNV detection. Bioinformatics 2016; 32(21): 3298–3305.
- 36 Ensembl. Nucleic acids research. Oxford, UK: Oxford Academic; 2019.
- 37Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010; 26(6): 841–842.
- 38Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Genetics of Parkinson's disease: an introspection of its journey towards precision medicine. Neurobiol Dis 2020; 137: 104782.
- 39Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson's disease. Rev Neurol (Paris) 2018; 174(9): 628–643.
- 40 SurajGupta/r-source GitHub. https://github.com/SurajGupta/r-source
- 41 R: The R Project for Statistical Computing. https://www.r-project.org/
- 42Therneau TM, Lumley T, Elizabeth A, et al. Survival: survival analysis. https://CRAN.R-project.org/package=survival. Accessed June 2020.
- 43Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006; 444(7118): 444–454.
- 44Jakobsson M, Scholz SW, Scheet P, et al. Genotype, haplotype and copy-number variation in worldwide human populations. Nature 2008; 451(7181): 998–1003.
- 45Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342(21): 1560–1567.
- 46Sun M, Latourelle JC, Wooten GF, et al. Influence of heterozygosity for Parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol 2006; 63(6): 826–832.
- 47Oliveira SA, Scott WK, Martin ER, et al. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 2003; 53(5): 624–629.
- 48Marder KS, Tang MX, Mejia-Santana H, et al. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol 2010; 67(6): 731–738.
- 49Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson's disease for parkin mutations. Neurology 2002; 58(8): 1239–1246.
- 50Periquet M, Latouche M, Lohmann E, et al. Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain 2003; 126(6): 1271–1278.
- 51Camacho JLG, Jaramillo NM, Gómez PY, et al. High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease. Mov Disord 2012; 27(8): 1047–1051.
- 52Yu E, Rudakou U, Krohn L, et al. Analysis of heterozygous PRKN variants and copy number variations in Parkinson's disease. Mov Disord 2020. https://doi.org/10.1002/mds.28299
- 53Robak LA, Du R, Yuan B, et al. Integrated Sequencing & Array Comparative Genomic Hybridization in familial Parkinson's disease. Neurol Genet 2020; 6(5):e498 2019/11/11/.
- 54Cornejo-Olivas M, Torres L, Mata IF, et al. A Peruvian family with a novel PARK2 mutation: clinical and pathological characteristics. Parkinsonism Relat Disord 2015; 21(5): 444–448.
- 55Pankratz N, Kissell DK, Pauciulo MW, et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 2009; 73(4): 279–286.
- 56Huttenlocher J, Stefansson H, Steinberg S, et al. Heterozygote carriers for CNVs in PARK2 are at increased risk of Parkinson's disease. Hum Mol Genet 2015; 24(19): 5637–5643.
- 57Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6(7): 652–662.
- 58Genovese G, Handsaker RE, Li H, et al. Using population admixture to help complete maps of the human genome. Nat Genet 2013; 45(4): 406–414.e1–e2.
- 59Lou H, Li S, Jin W, et al. Copy number variations and genetic admixtures in three Xinjiang ethnic minority groups. Eur J Hum Genet 2015; 23(4): 536–542.